Boothbay Fund Management
NVCR icon

Boothbay Fund Management’s NovoCure NVCR Stock Holding History

Boothbay Fund Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-142,700
Closed -$8.58M – 2137
2023
Q1 		$8.58M Buy
142,700
+35,800
+33% +$2.86M 0.18% 103
2022
Q4 		$7.84M Buy
+106,900
New +$8.04M 0.18% 97
2021
Q4 		– Sell
-27,000
Closed -$3.14M – 2113
2021
Q3 		$3.14M Buy
+27,000
New +$4.08M 0.09% 282

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Soleus Capital Management
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Quantinno Capital Management
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Boothbay Fund Management's NVCR Position: Q2 2026 in Review

Boothbay Fund Management sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 82,412 shares — an estimated $898K sold.

Boothbay Fund Management first reported a position in NVCR in Q1 2023 and held it in 3 quarters. The position peaked at $2.14M in Q1 2023. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

  • Boothbay Fund Management reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 82,412 NovoCure shares in Q2 2026, an estimated $898K.
  • Boothbay Fund Management first reported a position in NovoCure in Q1 2023 and held it in 3 quarters.
  • Boothbay Fund Management's NovoCure position peaked at $2.14M in Q1 2023.
  • 218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.